Amgen Inc. (FRA:AMG)
Germany · Delayed Price · Currency is EUR | Market Cap | 128.38B |
| Revenue (ttm) | 29.73B |
| Net Income (ttm) | 5.64B |
| Shares Out | n/a |
| EPS (ttm) | 10.41 |
| PE Ratio | 22.78 |
| Forward PE | 13.65 |
| Dividend | 8.59 (3.59%) |
| Ex-Dividend Date | Aug 22, 2025 |
| Volume | 2,996 |
| Average Volume | 797 |
| Open | 238.05 |
| Previous Close | 239.55 |
| Day's Range | 236.70 - 240.45 |
| 52-Week Range | 230.75 - 308.50 |
| Beta | n/a |
| RSI | 36.74 |
| Earnings Date | Oct 30, 2025 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial numbers in USD Financial StatementsNews
AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
THOUSAND OAKS, Calif. and TOKYO , Sept.
September Dogs Of The Dow Unleash One Ideal 'Safer' DiviDog
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are well-covered. Analyst forecasts suggest top Dow Dogs could de...
AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , Sept. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 9:15 a.m.
Today's Analyst Rating Update on Amgen (AMGN) | AMGN Stock News
Today's Analyst Rating Update on Amgen (AMGN) | AMGN Stock News
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Amgen Inc. (AMGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Amgen dips after trial update for Zai Lab partnered gastric cancer therapy
Amgen (AMGN) Plans $500M Investment for New Innovation Center
Amgen (AMGN) Plans $500M Investment for New Innovation Center
Organon and Henlius get FDA nod for Amgen biosimilars
Amgen to spend more than $500M to build new R&D center in California
Amgen Inc (AMGN) Announces $600 Million Investment in New Science and Innovation Center | AMGN ...
Amgen Inc (AMGN) Announces $600 Million Investment in New Science and Innovation Center | AMGN stock news
AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS
Research and Development Infrastructure Investment Expected to Create Hundreds of U.S. Jobs THOUSAND OAKS, Calif. , Sept. 2, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to invest...
Amgen to invest $600 million in new research and development facility in California
It is the latest U.S. investment by a drugmaker as President Donald Trump threatens to impose tariffs on pharmaceuticals imported into the U.S.
AMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , Aug. 29, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 Wells Fargo Healthcare Conference at 10:15 a.m.
Veeva partners with Amgen to speed up clinical trials
Calls of the Day: Micron, DoorDash, Amer Sports, Amgen, Merck and Costco
The Investment Committee debate the latest Calls of the Day.
Calls of the Day: Micron, DoorDash, Amer Sports, Amgen, Merck and Costco
The Investment Committee debate the latest Calls of the Day.
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
BeOne Medicines Ltd . (NASDAQ: ONC) on Monday agreed to sell its royalty rights on the worldwide sales, excluding China, of Amgen Inc.’s (NASDAQ: AMGN) Imdelltra (tarlatamab-dlle) for up to $950 mil...
REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
THOUSAND OAKS, Calif. , Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to in...
Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million
Royalty Pharma said on Monday it has signed a deal with BeOne Medicines to acquire a royalty interest in Amgen's drug for small cell lung cancer for up to $950 million.
Royalty Pharma to buy royalty interest in Amgen’s Imdelltra for up to $950M
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it has entered into an agreement to sell its royalty rights on the worldwide sales, excluding C...
SA analyst upgrades/downgrades: COHR, AMGN, KKR, SOFI
Back To Basics: Why I Favor Amgen Over Johnson & Johnson
August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys
Verizon is the only Dow stock currently meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are supported by free cash flow. Analyst forecasts suggest top Dow...